治療用リガンドは,エストロゲン受容体機能を阻害し,その運動性を損なう
Jane Guan1, Wei Zhou1, Marc Hafner2
1Department of Translational Oncology, Genentech, South San Francisco, CA 94080, USA.
Cell
|July 30, 2019
まとめ
エストロゲン受容体 (ER) 退廃を最適化することは,乳がんにおける完全な対抗性を保証するものではありません. ERの核移動を 抑制するのではなく 抑制することで ERの活動を抑制し 新しい治療戦略を 提供します
科学分野:
- 腫瘍学
- 分子生物学
- 内分泌学
背景:
- エストロゲン受容体陽性 (ER+) 乳がんは,内分泌療法に対する耐性にもかかわらず,しばしばERに依存している.
- フルヴェストラントはERの完全な抗体であり,ERの分解を介して作用すると考えられていますが,物理化学的性質は悪いです.
- 改善された特性を持つER分解剤の開発は,重要な治療目標です.
研究 の 目的:
- ERの劣化とERの対抗性の関係を調査する.
- ERアンタゴニストがER活動を抑制するメカニズムを探求する.
- 転写因子の移動性を標的とした治療の可能性を評価する.
主な方法:
- 転写活動と乳がん細胞の増殖抑制効果に関するER退廃剤の評価
- ERの核の移動とターンオーバーに対する敵対者の影響を分析する.
- ERの不動化と 転写抑制の関連を調査する
主要な成果:
- ER降解剤は,分解のみに依存しない,転写活動と反増殖の可能性のスペクトルを示します.
- フルベストラント類の抗薬は,ERの核内移動性を著しく低下させ,ERの活動を抑制する.
- ERの不動化は,ERのターンオーバーを増加させ,対抗に寄与します.
結論:
- 最適化されたER分解は,完全なER対抗とは等しくありません.
- 転写因子の移動性,特にER核の移動性は,ER対抗性の実行可能なメカニズムである.
- 転写因子モビリティをターゲットにすることで,ER依存性がんの新たな治療戦略が生まれます.
さらに関連する動画
14:13Detecting Estrogenic Ligands in Personal Care Products using a Yeast Estrogen Screen Optimized for the Undergraduate Teaching Laboratory
Published on: January 1, 2018
13.7K
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
944
関連する概念動画
Ligand Binding and Linkage
5.5K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.5K
Agonism and Antagonism: Quantification
1.0K
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
1.0K
Internal Receptors
74.3K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.3K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
3.8K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.8K
Ligand Binding Sites
14.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
14.9K
Combined Effects of Drugs: Antagonism
11.6K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.6K
